Fairhead S M, Chipping P M, Gordon-Smith E C
Br J Haematol. 1983 Sep;55(1):7-16. doi: 10.1111/j.1365-2141.1983.tb01219.x.
Thirty-one patients with aplastic anaemia were treated with antilymphocyte globulin (ALG) followed by anabolic steroids. All patients were reviewed at least 1 year after receiving treatment. Twenty-one patients were considered to have a severe form of aplasia. ALG from three sources was used during the trial. Sixteen patients were alive at the time of analysis, eight who had had severe aplastic anaemia (38%) and five of these no longer require blood support. No difference in response was found according to type of ALG used. Patients with a long history of aplasia before treatment fared worse than those with a short history. These results were better than those obtained with anabolic steroids alone in historical controls. It is concluded that ALG treatment is worth giving to patients with aplastic anaemia but that the optimum way of giving this immunosuppression may be different from that used in this presentation.
31例再生障碍性贫血患者接受抗淋巴细胞球蛋白（ALG）治疗，随后使用同化激素。所有患者在接受治疗后至少随访1年。21例患者被认为患有严重型再生障碍性贫血。试验期间使用了来自三种来源的ALG。分析时16例患者存活，其中8例曾患有严重再生障碍性贫血（38%），其中5例不再需要输血支持。根据所用ALG的类型，未发现反应差异。治疗前再生障碍性贫血病史长的患者比病史短的患者预后差。这些结果优于历史对照中单独使用同化激素所获得的结果。得出的结论是，ALG治疗对再生障碍性贫血患者是值得的，但给予这种免疫抑制的最佳方式可能与本研究中所用方式不同。
